[1] BYRNE R A, SARAFOFF N, KASTRATI A, et al. Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment[J]. Drug Saf,2009,32(9):749-770
[2] VALGIMIGLI M, BUENO H, BYRNE R A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS[J]. Eur J Cardiothorac Surg,2018,53(1):34-78
[3] LEVINE G N, BATES E R, BITTL J A, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American college of cardiology/ American heart association task force on clinical practice guidelines[J]. J Am Coll Cardiol,2016,68(10):1082-1115
[4] BONACA M P, BHATT D L, COHEN M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction[J]. N Engl J Med,2015,372(19):1791-1800
[5] YEH R W, SECEMSKY E A, KEREIAKES D J, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention[J]. JAMA,2016,315(16):1735-1749
[6] BABER U, MEHRAN R, GIUSTINO G, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from Paris[J]. J Am Coll Cardiol,2016,67(19):2224-2234
[7] GRANGER C B, GOLDBERG R J, DABBOUS O, et al. Predictors of hospital mortality in the global registry of acute coronary events[J]. Arch Intern Med,2003,163(19):2345-2353
[8] MEHRAN R, POCOCK S J, NIKOLSKY E, et al. A risk score to predict bleeding in patients with acute coronary syndromes[J]. J Am Coll Cardiol,2010,55(23):2556-2566
[9] DETSKY A S, NAYLOR C D, O'ROURKE K, et al. Incorporating variations in the quality of individual randomized trials into meta-analysis[J]. J Clin Epidemiol,1992,45(3):255-265
[10] GWON H C, HAHN J Y, PARK K W, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of xience/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study[J]. Circulation,2012,125(3):505-513
[11] KIM B K, HONG M K, SHIN D H, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (Real safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation)[J]. J Am Coll Cardiol,2012,60(15):1340-1348
[12] FERES F, COSTA R A, ABIZAID A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial[J]. JAMA,2013,310(23):2510-2522
[13] COLOMBO A, CHIEFFO A, FRASHERI A, et al. Second-generation drug-eluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial[J]. J Am Coll Cardiol,2014,64(20):2086-2097
[14] GILARD M, BARRAGAN P, NORYANI A A L, et al. 6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial[J]. J Am Coll Cardiol,2015,65(8):777-786
[15] SCHULZ-SCHUPKE S, BYRNE R A, TEN BERG J M, et al. Intracoronary stenting and antithrombotic regimen: safety and efficacy of 6 months dual antiplatelet therapy after drug-eluting stenting (ISAR-SAFE) trial investigators. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting[J]. Eur Heart J,2015,36:1252-1263
[16] HONG S J, SHIN D H, KIM J S, et al. 6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial[J]. JACC Cardiovasc Interv,2016,9(14):1438-1446
[17] HAN Y L, XU B, XU K, et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial[J]. Circ Cardiovasc Interv,2016,9(2):e003145
[18] NAKAMURA M, ⅡJIMA R, AKO J, et al. Dual antiplatelet therapy for 6 versus 18 months after biodegradable polymer drug-eluting stent implantation[J]. JACC Cardiovasc Interv,2017,10(12):1189-1198
[19] LEE B K, KIM J S, LEE O H, et al. Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy[J]. EuroIntervention,2018,13(16):1923-1930
[20] HAHN J Y, SONG Y B, OH J H, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial[J]. Lancet,2018,391(10127):1274-1284
[21] KEDHI E, FABRIS E, VAN DER ENT M, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial[J]. BMJ,2018:k3793
[22] VALGIMIGLI M, CAMPO G, MONTI M, et al. Prolonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study (PRODIGY) investigators. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial[J]. Circulation,2012,125:2015-2026
[23] MAURI L, KEREIAKES D J, YEH R W, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents[J]. N Engl J Med,2014,371(23):2155-2166
[24] COLLET J P, SILVAIN J, BARTHÉLÉMY O, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial[J]. Lancet,2014,384(9954):1577-1585
[25] LEE C W, AHN J M, PARK D W, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial[J]. Circulation,2014,129(3):304-312
[26] PARK S J, PARK D W, KIM Y H, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents[J]. N Engl J Med,2010,362(15):1374-1382
[27] GARRATT K N, WEAVER W D, JENKINS R G, et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after Taxus Liberté paclitaxel-eluting coronary stent placement[J]. Circulation,2015,131(1):62-73
[28] COSTA F, VRANCKX P, LEONARDI S, et al. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging dual-antiplatelet treatment after grading stent-induced intimal hyperplasia) trial[J]. Eur Heart J,2015,36(20):1242-1251
[29] SABATÉ M, RÄBER L, HEG D, et al. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical evaluation of the xience-V stent in acute myocardial infarction) and COMFORTABLE-AMI (comparison of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial infarction) trials[J]. JACC Cardiovasc Interv,2014,7(1):55-63
[30] 中华医学会心血管病学. 2013年抗血小板治疗中国专家共识[J]. 中华心血病杂志, 2013, 40(3):183-194